Dr. Luke Pase

Dr. Luke Pase is the Chief Technology Officer at Anocca AB, with over 20 years of experience in genetics, molecular immunology, synthetic biology, and cell engineering. He has applied a broad range of gene modification tools across diverse organisms and mammalian cell systems at scale. 

Luke was among the first team members at Anocca AB, where he helped establish the company’s mammalian cell engineering workflows and forward biology screening platform. As a key inventor of several proprietary technologies, he now leads Anocca’s R&D TCR platform, overseeing the discovery and de-risking of a comprehensive library of TCR assets for clinical development. He also leads a team that drives the integration of non-viral gene editing, enhanced effector function, and synthetic biology approaches to enable scalable manufacturing of potent TCR-T cell therapies.